ZINPLAVA, also known by its generic name bezlotoxumab, is a monoclonal antibody medication designed for the prevention of the recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are at high risk for CDI recurrence. It is not used to treat active infections but works by targeting and neutralizing a specific toxin produced by the Clostridium difficile bacteria, thereby preventing the recurrence of the infection. ZINPLAVA is administered as an intravenous infusion and is often used in conjunction with antibiotic treatment for CDI. It provides a targeted approach to managing the condition, focusing on those patients who are most vulnerable to repeated infections.